ClinicalTrials.gg
Status unknownNCT02759094Updated Apr 6, 2023

Evaluation of Safety and Effectiveness of the RefluxStop Device in the Management of GERD

An interventional study of Treatment with RefluxStop in GERD, sponsored by Implantica CE Reflux Ltd.. Status unknown at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-06.

Sponsored by Implantica CE Reflux Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Gastroesophageal Reflux with a site in Hungary — none open to participants now, none under way, none of them phase 3. Gastroesophageal Reflux · Hungary.

Enrollment
15th of 15
50 · median 628
Started
2016
the only one that year
No phase
Only one
of the 15
Registered
14th of 15
by date
Lead sponsor
1 of 15
Implantica CE Reflux Ltd.

Among the 15 studies in Gastroesophageal Reflux with a site in Hungary, this one is the 15th largest by enrollment, is the only one that started in 2016, is the only one with no phase, and was the 14th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 15 studies in Gastroesophageal Reflux with a site in Hungary is open now. The open studies under Gastroesophageal Reflux, anywhere →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Gastroesophageal Reflux with a site in Hungary as a file.
02

Study summary

Prospective, open-label, multi-centre, single arm treatment only trial to evaluate the safety and effectiveness of RefluxStop for the treatment of GERD.

The used medical device "RefluxStop" is an implantable single use sterile device to ensure maintenance of gastro oesophageal junction (GEJ) in an intra-abdominal position to reduce or eliminate GERD.

Read the detailed description

The study plan will include a screening/baseline visit, a surgical procedure phase with hospital stay until discharge, and study visits at 6 weeks, 3 months and 6 months after device implantation.

A follow-up will be performed annually from years 1-5 to evaluate long-term safety and performance with the intention to collect post-market long-term data using the GERD-HRQL score as a screening tool. Data of subjects who agreed to participate in the long-term safety and performance will be analysed after 1, 2, 3, 4 and 5 years.

At the screening/baseline visit, after signing the informed consent, the eligibility of subjects to receive treatment with the study device will be determined. Eligible subjects will then undergo the device implant procedure.

A standard laparoscopic approach will be used to reposition the lower esophageal sphincter (LES) to its intra-abdominal position. The RefluxStop™ device will then be positioned and fixed in the gastric fundus to ensure intra-abdominal positioning of the GEJ at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed. The procedure will be recorded and saved only with study identification number and without subject ID information. The same applies for images on contrast swallow controlling the device.

Evaluations will be performed daily during hospitalisation and in an additional 3 study visits in the outpatient setting at 6 weeks, 3 months and 6 months. Subjects who have given their consent to participate in the long-term safety and performance follow-up part of the study will be followed annually from year 1-5.

A pathologically low pH in the lower esophagus is correlated to the development of precancerous changes/ Barrett's esophagus and fulminant cancer, as shown in the literature. Barrett's esophagus occurs in 1-2% of the total population while daily acid reflux patients have an incidence of 10-20% depending on the severity of the acid reflux [Modiano, Gerson 2007; Cossentino, Wong 2003]. As many as 48,000 people p.a. die in Europe and the US alone of esophageal adenocarcinoma, the primary cause of which is acid reflux. Therefore, in order to determine whether treatment is maintained in the longer-term, an additional 24-hour pH monitoring and simplified contrast swallow x-ray to verify the position of the device will be performed at 5 years for the benefit of the patients.

These long-term results have also been requested by the U.S. FDA. A quality control of the placement of the device will be categorized for subjects at after surgery, 6 months and 5 year follow-up and at therapy failure.

The position of the device is of utmost importance and will be categorized in the case of therapy failure.

To ensure a proper quality control, the contrast swallow x-ray determining eventual hiatal hernia performed before surgery is repeated at hospital stay after surgery and during the 6-month surgical outcome control and at 5-year follow-up. This x-ray is also used for categorizing the position of the device in a four-graded scale if therapy failure occurs and should be performed by the radiologist using the standard of care post-op contrast swallow.

03

Conditions studied

  • GERD

Keywords

  • GERD
  • Implantable medical device
  • RefluxStop
  • Reflux
  • Gastroesophageal Reflux
  • Laparoscopy
  • pH-Monitoring
  • PPI proton pump inhibitors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's age >= 18 years and \<= 75 years
  • Subject is able to undergo general anaesthesia and is a suitable laparoscopic surgical candidate
  • Subject is willing and able to participate
  • Subject has provided written after being informed of the study procedure and risks prior to any study-related events
  • Subject has documented typical GERD symptoms present for > 6 months which respond to PPIs as anti-GERD medication. Typical symptom of GERD is defined as heartburn, which is a burning epigastric or substernal pain
  • Subject requires daily PPI anti GERD medication
  • Subject has a 24-hour pH monitoring proven GERD performed taken off any anti reflux medication or after discontinuation for at least 7 days prior to testing. Total distal esophageal pH must be \<= 4 for >= 4.5% if time during a 24-hour monitoring

Exclusion criteria

Exclusion Criteria:

  • Subject is currently participating in another study involving drugs or devices
  • Subject has a history of gastro esophageal surgery, anti-reflux or bariatric procedure
  • Subject has a history of endoscopic anti-reflux intervention
  • Subject has a history or a suspicion of esophageal or gastric cancer
  • Subject has a history of major psychiatric disorder
  • Presence of a para-esophageal hernia or sliding hernia of > 3cm determined on endoscopy
  • Presence of an esophagitis grade C or D according to the Los Angeles classification
  • Presence of esophageal dysmotility disorder such as but not limited to scleroderma, achalasia, Nutcracker oesophagus
  • Presence of esophageal stricture or stenosis
  • Presence of delayed gastric emptying
  • Presence of esophageal or gastric varies
  • Subject has a (BMI) > 35kg/m2
  • Female subjects who are pregnant or nursing
  • Known sensitivity or allergies to silicone materials
  • Subjects who are unable to comply with the protocol requirements
  • Subjects with limited (\< 3 years)
  • Intra-operative findings that may preclude conduct of the study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Treatment with RefluxStop device

    All enrolled subjects will receive treatment for their GERD using the RefluxStop device intervention

    Device: Treatment with RefluxStop

Interventions

  • DeviceTreatment with RefluxStop

    A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.

06

What researchers measure

Primary outcomes

  1. Primary safety endpoint

    Assessment of incidence of serious adverse device effects (SADEs) and procedure-related serious adverse events (SAEs)

    Time frame: at 6 months

  2. Primary efficacy endpoint

    Percent reduction from baseline of GERD symptoms based on the GERD-HRQL score (questions 1-10). The data will also be presented as the number of subjects obtaining a 50% improvement of the baseline figures, with success defined as 60% of the subjects to reach such score improvement. Thus, the aim of this analysis is to show that the lower limit of the confidence interval exceeds 60%.

    Time frame: at 6 months

Secondary outcomes

  1. Secondary safety endpoint

    Assessment of incidence of serious adverse device effects (SADEs) and procedure-related serious adverse events (SAEs). Incidence of adverse device effects (ADEs) and procedure-related adverse events (AEs)

    Time frame: at 6 weeks, 3 months, 6 months (ADEs and AEs only) and annually years 1-5

  2. Secondary efficacy endpoint: HRQL all other timepoints

    Percent reduction from baseline of GERD symptoms based on the GERD-HRQL score (questions 1-10)

    Time frame: measured at baseline, 6 weeks, 3 months and follow-up years 1-5

  3. Secondary efficacy endpoint: additional questions

    Reduction from baseline of GERD symptoms based on the total GERD-HRQL score (questions 1-10) and individual symptom questions

    Time frame: measured at baseline, 6 weeks, 3 months, 6 months and follow up years 1-5

  4. Secondary efficacy endpoint: 24-hr pH monitoring

    Reduction or normalisation from baseline of the total acid (pH\<4) exposure time on 24-hour pH monitoring

    Time frame: measured at baseline, 6 months, 5 years and if therapy failure

  5. Secondary efficacy endpoint: PPI usage

    Reduction from baseline of the percentage of subjects with regular daily PPI usage

    Time frame: measured at baseline, 6 weeks, 3 months, 6 months and follow up years 1-5

  6. Secondary efficacy endpoint: Foregut

    Reduction from baseline of individual foregut questionnaire scores focusing on regurgitation and additional information on dysphagia and odynophagia reported as AEs, or alternatively GERD-HRQL questions \>2 and/or \>3

    Time frame: measured at baseline, 6 weeks, 3 months, 6 months and follow up years 1-5

  7. Secondary efficacy endpoint: Endoscopy

    Improvement in esophagitis on upper endoscopy

    Time frame: measured at baseline, 6 months and if therapy failure

  8. Secondary efficacy endpoint: device location

    Location and function of the device evaluated by a simplified contrast swallow x-ray with overview pictures of device and LES position during swallowing

    Time frame: measured at hospital stay, 6 weeks, 6 months, 5 years and if therapy failure

Other outcomes

  1. Secondary efficacy subgroup endpoint

    Reduction or change comparison based on the following subgroups: age, gender, weight and result of baseline total GERD-HRQL score, comparing the following secondary endpoints: the total acid (pH\<4) exposure time on routine 24-hour pH monitoring at month 6 and the number and percentage of subjects having verified therapy failure

    Time frame: per patient any point in the study triggered either by regular daily PPI usage or a GERD-HRQL score with less than 50% improvement compared to baseline, and having been verified as therapy failure via 24-hr pH monitoring and x-ray results

  2. Exploratory endpoint: procedure complications

    Assess any procedure-related complications

    Time frame: during procedure

  3. Exploratory endpoint: Procedure time

    Assess time to perform the procedure

    Time frame: during procedure

  4. Exploratory endpoint: length of hospital stay

    Assess length of the subject's hospital stay

    Time frame: from date of admission to date of discharge, assessed up to 100 months

07

Study locations

4 sites
  • Semmelweis University
    Budapest, 1082, Hungary
  • University of Debrecen, Kenezy Gyula Teaching Hospital, General Surgery Department
    Debrecen, 4031, Hungary
  • Fejer County Szent Gyorgy University Teaching Hospital, Surgical Department
    Székesfehérvár, H-8000, Hungary
  • Clinical Center of Serbia, Clinic for Digestive Surgery
    Belgrade, 11000, Serbia
08

References and documents

Publications

  • Bjelovic M, Harsanyi L, Altorjay A, Kincses Z, Forsell P; Investigators of the RefluxStop Clinical Investigation Study Group. Non-active implantable device treating acid reflux with a new dynamic treatment approach: 1-year results : RefluxStop device; a new method in acid reflux surgery obtaining CE mark. BMC Surg. 2020 Jul 20;20(1):159. doi: 10.1186/s12893-020-00794-9. PubMed 32689979 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Mar 2018, 15 months.

Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 15 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2016
First posted
May 3, 2016
StartActual
Dec 2016
Primary completionActual
Mar 2018
CompletionEst.
Dec 2023
Last update
Apr 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02759094
Lead sponsor
Implantica CE Reflux Ltd.
Responsible party
Sponsor
First posted
May 3, 2016
Start date
Dec 2016
Primary completion
Mar 2018
Completion
Dec 2023 (estimated)
Last update
Apr 6, 2023

Study contacts

László Harsányi, Prof.
principal investigator · Semmelweis University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion